New therapy for refractory multiple myeloma

摘要

The FDA granted accelerated approval to the oral exportin 1 (XPO1) inhibitor selinexor (Xpovio) used in combination with the corti-costeroid dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.